Caliper Life Sciences, Inc. this week introduced its latest video-imaging system. The IVIS Kinetic system is designed to see activity at the molecular level through non-invasive means. It’s the latest in a long line of preclinical imaging systems, including high-sensitivity bioluminescence and fluorescence molecular. The main difference is the video capability. This additional capability, the company states in a news release, “will further advance cardiovascular, neurology, immunology and oncology distribution studies conducted.”
The IVIS system enhances analysis of gene expression, cellular pathways and the body’s response to drugs. The current and intended application of the imaging is to track speed of reaction with drug use in lab animals and any different behaviors in lab animals.
“The IVIS Kinetic imaging system provides a window for scientists to view biological events as they happen,” said Kevin Hrusovsky, Caliper Life Sciences president and CEO. “This system is another great example of how Caliper Life Sciences is helping pharma and biotech companies understand complex biological processes to accelerate the discovery of successful drug candidates.”
Caliper’s IVIS imaging systems have played a significant role in demonstrating the usefulness of various drugs, including Sutent (Pfizer), Sprycel (Bristol-Myers Squibb), Tasigna ((Novartis), and Cubicin (Cubist Pharmaceuticals).
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
